The pharmacogenomics journal

01 12 October 2026

DOI 10.1038/s41397-026-00432-2

Real-world analysis of genotype-guided treatment for carriers of actionable DPYD and UGT1A1 variants

Open DOI

Amy L. Pasternak, William Tackett, Mousumi Banerjee et al.

This retrospective, matched, case-control study was conducted to compare rates of severe adverse events (SAE) within the first three treatment cycles in DPYD and UGT1A1 variant carriers who received genotype-guided treatment compared to ...

Read abstract

02 5 October 2026

DOI 10.1038/s41397-026-00433-1

Bridging the pharmacogenomics gap: a survey of healthcare workers in South-Western Nigeria

Open DOI

Ochuko M. Orherhe, Omolabake F. Ayodele, Jeremiah O. Omojuyigbe et al.

This study assessed the knowledge, attitude, and perception of pharmacogenomics among healthcare workers in Southwest Nigeria. A structured, questionnaire-based survey was administered to 229 healthcare workers in Southwestern Nigeria us...

Read abstract

03 1 October 2026

DOI 10.1038/s41397-026-00430-4

The role of pharmacogenomics in epilepsy treatment: advancements in personalized medicine

Open DOI

Najmeh Ahangari, Mohammad Doosti, Mojtaba Safi et al.

Epilepsy is a diverse and often severe neurological disorder characterized by frequent and unpredictable seizures caused by the simultaneous discharge of brain cells in one or both hemispheres. Recently, there has been a significant shif...

Read abstract

04 28 September 2026

DOI 10.1038/s41397-026-00431-3

Risk of drug-induced liver injury in multiple system atrophy patients treated with KM-819 is potentially associated with the HLA-DPB1*05:01:01:01 allele

Open DOI

Jeong-Hoon Han, Raúl J. Andrade, Einar Stefán Björnsson et al.

KM-819, a first-in-class inhibitor of Fas-associated factor 1 (FAF1), was investigated in a Phase 2 clinical trial in Korean patients with multiple system atrophy (MSA). Among 34 KM-819-treated patients, 11 met the case definition for su...

Read abstract

05 9 September 2026

DOI 10.1038/s41397-026-00426-0

Barriers and facilitators to the implementation of pharmacogenomic testing for antidepressants use in primary care: a systematic review using the consolidated framework for implementation research

Open DOI

Muireann Counihan, Deirdre Cushen, Sookyung Kwak et al.

Pharmacogenomic (PGx) testing may improve antidepressant prescribing, but uptake in primary care is limited. The Consolidated Framework for Implementation Research (CFIR) can help identify determinants of implementation. To synthesise ba...

Read abstract

06 26 August 2026

DOI 10.1038/s41397-026-00429-x

Amplicon-based long-read sequencing for accurate CYP2D6 gene deletion and duplication detection using CYP2D7 as a reference gene

Open DOI

Kiflu Gebremicael Tesfamicael, Michael Musker, David L. Adelson et al.

We developed an amplicon-based long-read sequencing approach that enables simultaneous detection of CYP2D6 single-nucleotide variants (SNVs) and copy-number variations (CNVs) in a single reaction. The SNVs of the two pseudogenes, CYP2D7 ...

Read abstract

07 19 August 2026

DOI 10.1038/s41397-026-00428-y

Association between CYP2D6 genotype and treatment effectiveness and safety in 99 hospitalized patients with major depressive disorder a retrospective cohort study CYP2D6 genotype and antidepressant response

Open DOI

Aleksandra Petković Ćurčin, Aleksandra Jeremić, Danilo Joković et al.

Cytochrome P450 2D6 (CYP2D6) is a polymorphic enzyme that influences antidepressant metabolism. This retrospective cohort study investigated the association between CYP2D6 genotype and treatment outcomes in 99 hospitalized patients with ...

Read abstract

08 5 August 2026

DOI 10.1038/s41397-026-00424-2

Large-scale analysis demonstrates the influence of CYP2C19 genotype on specific SSRI side effects

Open DOI

Chris Eijsbouts, Yunxuan Jiang, James R. Ashenhurst et al.

09 30 July 2026

DOI 10.1038/s41397-026-00427-z

Effects of CYP3A4, CYP3A5, and ABCB1 genetic variants on tacrolimus metabolism during the early period after kidney transplantation

Open DOI

Nahathai Dukaew, Kajohnsak Noppakun, Mingkwan Na Takuathung et al.

10 25 July 2026

DOI 10.1038/s41397-026-00425-1

Understanding public perspectives on direct-to-consumer pharmacogenomic testing in the UK: a qualitative study

Open DOI

Amy Mathieson, Lisa Brunton, Stephanie Gillibrand et al.

Direct-to-consumer (DTC) pharmacogenomic (PGx) testing is expanding rapidly in the UK, yet no dedicated regulatory framework currently governs these services. Although a 2021 parliamentary inquiry recommended stronger safeguards and clea...

Read abstract